Description: A brief review of the 2024 SOA Health Meeting in Baltimore

Description: The coming wave of biosimilars could have a major impact on prescription drug spend in coming years. The big event of Humira biosimilar launches in 2023 will be significant in determining that ultimate impact. Payers are making coverage decisions. The more biosimilars are utilized, the greater the potential savings. How will biosimilar adoption be maximized?

Description: Patients with chronic conditions such as musculoskeletal pain, diabetes, and hypertension impact 50% of the US healthcare population, consume more than 85% of healthcare costs, and often require a higher volume of care, expensive imaging, testing, and emergency procedures, and long-term high-cost drugs. Managing these conditions through innovative digital health interventions provides a significant opportunity for higher-touch and more-effective management that will result in lower costs.

Description: America’s healthcare results are lackluster and worsening despite enormous effort and investment over many decades. Spending, affordability, health, coverage, access, quality, and healthcare workforce results are suboptimal or poor. Too many are suffering, and the system is financially unsustainable. We need a new approach, a new way of thinking about healthcare financing and delivery.

Description: If you are a pricing actuary, you have probably been there. A new blockbuster drug has been introduced and the manufacturer is claiming that the value of the drug will offset the higher cost of the drug. But how do you know? In this session, presenters will discuss techniques for measuring the impact of a prescription drug on the total cost of care, including the benefits and limitations of each method.

Description: This session, which borrows heavily from SOA studies, US government data, and Munich Re’s global health data, will explore the blending of Covid deaths into the new baseline mortality.

Description: This will be the most fun you'll ever have learning about applying health status based risk adjustment methodologies in the real world! Quantifying relative differences in the use of finite healthcare resources – due to differences in health status – isn't just fun, it's the very heart and soul of ASOP 45! Get ready for a rollercoaster of statistics, probability, and a few puns that might just make you laugh harder than a data outlier!

Description: This presentation seeks to educate SOA attendees on how Medicare provides care for HIV-positive members. HIV is a disease that has occupied a prominent place in the public's view since its initial discovery. Initially a terminal condition for the afflicted population, advances in anti-retroviral pharmaceutical therapies transformed HIV into a chronic condition in the 1990s.

Description: Join a dynamic two-part panel, where we'll delve into organizational and personal innovation strategies, tactics, and success stories. Begin by uncovering how venture studios, payor/employer partnerships, and startup business units can propel your company's innovative edge.

Description: Underwriting smokers just got a lot more interesting. New research reveals that tobacco’s mortality is surprisingly durable and tenacious. Mortality is now shown to hover at 200% for years after a reported incidence of nicotine dependency, and smoking turns many common and manageable conditions into serious comorbidities with compounded mortality impact.